诺和诺德一度崩跌28%!下一代减肥药数据不及预期 机构火线解读

东方财富
20 Dec 2024

被誉为“减肥药双雄”的诺和诺德,周五给全球投资者表演了一把“高位跳水”。由于备受期待的“下一代减肥药”数据不佳,截至发稿公司美股盘前一度下跌超28%,市值蒸发近千亿美元,随后跌幅收窄到20%以内——依然把2023年8月以后的涨幅全部回吐了。诺和诺德官网发布的研究显示,备受期待的CagriSema(卡格列肽+司美格鲁肽复方制剂),在试验对象坚持使用68周后,CagriSema组平均减重22.7%。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10